Roth Capital Partners initiated coverage of Bionano Genomics (NASDAQ:BNGO) with a “buy” rating and $12 price target. The stock closed at $6.31 on Sept. 24. Bionano is a life sciences instrumentation company that offers...
H.C. Wainwright raised its price target for Verastem (NASDAQ:VSTM) to $15 from $10 after the FDA approved Verastem’s lead product, Copiktra, as the first PI3K-delta and P13K-gamma inhibitor for the treatment of third...
H.C. Wainwright launched coverage of Krystal Biotech (NASDAQ:KRYS) with a “buy” rating and $32 price target. The stock closed at $16.88 on Sept 21. “We believe the company has the potential to become a leader in the...
H.C. Wainwright initiated coverage of Nanobiotix SA (PSE:NANO) with a “buy” rating and price target of €25. The stock closed at €16.60 on Sept. 21. Nanobiotix is developing NBTXR3, a radio-enhancer, which can improve...
Roth Capital Partners raised its price target for IRadimed (NASDAQ:IRMD) to $35 from $26 after updating its forward financial forecasts. The stock closed at $31.40 on Sept. 19. IRadimed is the world’s first and...
H.C. Wainwright initiated coverage of AVROBIO (NASDAQ:AVRO) with a “buy” rating and $47 price target. The stock closed at $39.63 on Sept. 13. AVROBIO is pioneering the development of lentiviral gene therapies as a...
H.C. Wainwright raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $23 from $16 after the company disclosed plans to reinstate dosing of new patients following the FDA decision to lift the partial...
Stifel initiated coverage of UroGen Pharma (NASDAQ:URGN) with a “buy” rating and $70 price target. The stock closed at $43.90 on Sept. 12. “We think UroGen offers investors an opportunity to own a company with a late...
Ladenburg Thalmann launched coverage of Rocket Pharmaceuticals (NASDAQ:RCKT) with a “buy” rating and $30 price target. The stock closed at $23.96 on Sept. 12. Rocket is developing potentially curative first-in-class...
Stifel launched coverage of Rhythm Pharmaceuticals (NASDAQ:RYTM) with a “hold” rating and $36 price target, saying the risk/reward for the shares is pretty balanced at current levels. The stock closed at $30.77 on Sept...